Thursday , April 9 2020
Home / ethiopia / PathogenDx Revolutionary Announces $ 7.5 Million Series B Funding

PathogenDx Revolutionary Announces $ 7.5 Million Series B Funding




<div _ngcontent-c15 = "" innerhtml = "

PathogenDx, Inc., an innovator in DNA-based pathogen testing technology for hemp, hemp, agriculture, and food safety, announced Monday that it received $ 7.5 million in funding. USA. The company was able to close this round of financing in just three months.

& nbsp; The headquarters of PathogenDx, headquartered in Scottsdale, Arizona, is to become the bearer of standards in DNA testing with its advanced microchip testing platform. Earlier this year, the company announced the wider use of its patented technology for the rapid identification of bacterial and fungal strains. PathogenDx technology can detect and identify up to 50 pathogens in a single test and deliver results in as little as six hours. This is 12 times faster than the centuries-old practice of testing a Petri dish. & Nbsp;

& nbsp; DNA testing companies DetectX ™, QuantX ™, and EnviroX ™ detect, identify and quantify pathogens hiding in cannabis crops such as E. coli, Salmonella and Aspergillus. This technology will help growing marijuana growers deliver safer foods while preventing millions of dollars in losses from contaminated or spoiled crops. & Nbsp;

& nbsp; With funding for Series B, the PathogenDx team will continue to expand its cutting-edge technology in food, medicine and agriculture testing, while continuing to strengthen its leadership position with its current portfolio of domestic and international customers in the cannabis industry. PathogenDx expects full federal approval of its technology by the first half of 2020. & Nbsp;

& nbsp; PathogenDx technology can be applied in any industry where it is necessary to test for pathogens for consumer safety. When we talk about E. Coli or another outbreak, six hours versus 72 hours can be a matter of life and death.

& nbsp; "PathogenDx will make a significant contribution to medical testing technology in the coming years," said Rami A. Tritt, MD, managing director of the Panther Opportunity Fund. “Germs are becoming increasingly drug resistant and playing an increasingly important role in community acquired infections and respiratory infections. Innovative testing technologies, such as the fast and specific identification of PathogenDx, will enable healthcare providers to better diagnose these infections and prevent the spread of preventable infections. diseases "& nbsp.

& nbsp; This last round of investments was made by Cresco Capital Partners with the participation of Altitude Investment Management, Arcadian Investment Partners, Panther Opportunity Fund LLC, Salveo Capital, Flatiron Venture Partners and other investors. & nbsp;

& nbsp; “We saw great value by investing in a company that enhances the overall security of the cannabis supply chain,” said John Trauben of Altitude Investment Management. “These days, the main thing is safety, the support of a company that provides pure cannabis has provided an excellent opportunity to invest in a business that succeeds by doing good.”

& nbsp; For more information on how you can use this simple, powerful, and inexpensive DNA-based pathogen test, visit www.pathogendx.com.

& Nbsp;

& Nbsp;

">

PathogenDx, Inc., an innovator in DNA-based pathogen testing technology for hemp, hemp, agriculture, and food safety, announced Monday that it received $ 7.5 million in funding. USA. The company was able to close this round of financing in just three months.

Headquartered in Scottsdale, Arizona, PathogenDx's mission is to become the standard-bearer of DNA-based testing with its industry-leading microchip testing platform. Earlier this year, the company announced the wider use of its patented technology for the rapid identification of bacterial and fungal strains. PathogenDx technology can detect and identify up to 50 pathogens in a single test and deliver results in as little as six hours. This is 12 times faster than the centuries-old practice of testing a Petri dish.

DNA testing companies DetectX ™, QuantX ™ and EnviroX ™ detect, identify and quantify pathogens hiding in cannabis crops such as E. coli, Salmonella and Aspergillus. This technology will help growing marijuana growers deliver safer foods while preventing millions of dollars in losses from contaminated or spoiled crops.

With its B-Series funding, the PathogenDx team will continue to expand its cutting-edge technology in food testing, medicine and agriculture, while continuing to strengthen its leadership position with its current portfolio of domestic and international customers in the cannabis industry. PathogenDx expects full federal approval of its technology by the first half of 2020.

PathogenDx technology can be used in any industry where there is a need for testing for pathogens for consumer safety. When we talk about E. Coli or another outbreak, six hours versus 72 hours can be a matter of life and death.

“PathogenDx will make a significant contribution to medical testing technology in the coming years,” said Rami A. Tritt, MD, managing director of the Panther Opportunity Fund. “Germs are becoming increasingly drug resistant and playing an increasingly important role in community acquired infections and respiratory infections. Innovative testing technologies, such as the fast and specific identification of PathogenDx, will enable healthcare providers to better diagnose these infections and prevent the spread of preventable infections. disease. "

This last investment round was held by Cresco Capital Partners with the participation of Altitude Investment Management, Arcadian Investment Partners, Panther Opportunity Fund LLC, Salveo Capital, Flatiron Venture Partners and other investors.

“We saw great value by investing in a company that enhances the overall security of the cannabis supply chain,” said John Trauben of Altitude Investment Management. “These days, the main thing is safety, the support of a company that provides pure cannabis has provided an excellent opportunity to invest in a business that succeeds by doing good.”

For more information on how you can use this simple, powerful, and inexpensive DNA-based pathogen testing, visit www.pathogendx.com.


Source link